Get Integrated Data for Your Specialty and Interest Aresa
 
Category Select :
Items 1 ~ 20 of 955, Page 1 of 49
1. WHO recommends dolutegravir as preferred HIV treatment option in all populations - 07/22/2019
 WHO
2. FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available - 07/17/2019
 MERCK
3. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access - 07/09/2019
 WHO
  New essential medicines and diagnostics lists published today
4. One in 3 Cancer Survivors Has Chronic Pain - 06/28/2019
 American Cancer Society
  Many survivors don’t get help for side effects
5. In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance - 06/18/2019
 WHO
6. FDA approves first generic naloxone nasal spray to treat opioid overdose - 04/19/2019
 U.S. FOOD & DRUG ADMINISTRATION
  Agency is also taking new steps to support development of over-the-counter and additional generics of naloxone to help reduce opioid overdose deaths, increase access to emergency treatment
7. Statement on new steps to strengthen agency’s safety requirements aimed at mitigating risks associated with transmucosal immediate-release fentanyl products - 03/27/2019
 U.S. FOOD & DRUG ADMINISTRATION
8. Medtronic Announces FDA Clearance and U.S. Launch of the Accurian Radio Frequency System for Nerve Tissue Ablation - 02/27/2019
 Medtronic
  Medtronic Expands Pain Portfolio with Minimally Invasive Therapy to Support Patients Throughout the Care Continuum
9. Statement from FDA Commissioner Scott Gottlieb, M.D. on the agency’s 2019 policy and regulatory agenda for continued action to forcefully address the tragic epidemic of opioid abuse - 02/26/2019
 U.S. FOOD & DRUG ADMINISTRATION
10. FDA statement from Commissioner announcing efforts to improve the quality of the information used to assess the effectiveness of REMS programs in supporting the safe use of medications - 01/24/2019
 U.S. FOOD & DRUG ADMINISTRATION
  Risk Evaluation and Mitigation Strategy (REMS)
11. New Data Reinforce Benefits of Abbott’s BurstDR™ Spinal Cord Stimulation for People Living with Chronic Pain - 01/19/2019
 Abbott
  Data from two recent studies presented at NANS 2019 demonstrate key benefits of BurstDR™ stimulation / Microdosing BurstDR stimulation at lowest effective energy allows patients to manage their pain without the burden of recharging their devices / Additional data further showed switching from other types of SCS therapies to Abbott’s BurstDR stimulation significantly reduced pain and the need for opioid medication
12. Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery - 01/17/2019
 Medtronic
  Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids
13. Pulsed Radiofrequency Relieves Acute Back Pain and Sciatica - 11/27/2018
 Radiological Society of North America
  Pulsed energy to treat acute lower back pain is safe and effective.
14. Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on transformative new steps to modernize FDA’s 510(k) program to advance the review of the safety and effectiveness of medical devices - 11/26/2018
 U.S. FOOD & DRUG ADMINISTRATION
  Modernizing the 510(k) Pathway“Safety and Performance Based Pathway” / Promoting Greater Transparency and Post-Market Surveillance
15. Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs - 11/16/2018
 U.S. FOOD & DRUG ADMINISTRATION
16. New Approvals Allow Chronic Pain Sufferers to Try Abbott''s Non-Opioid Pain Therapy Before Getting Device Implant - 11/15/2018
 Abbott
  Neurostimulation of the dorsal root ganglion (DRG) can provide pain relief for patients battling chronic pain when previous treatment options were unsuccessful / Abbott's new DRG Invisible Trial System brings an intuitive, wireless approach to the temporary evaluation giving patients the full benefits of DRG therapy prior to permanent implant
17. AMA President Outlines Efforts to Attack Dysfunction in Health Care - 11/14/2018
 American Medical Association
18. New $15 Million Initiative to Further Reimagine Physician Training - 10/30/2018
 American Medical Association (AMA)
  New AMA Reimagining Residency initiative is aimed at transforming residency training to ensure physician well-being and improved patient safety.
19. The overlooked benefits of medical scribes - 10/26/2018
 American Medical Association (AMA) News by Andis Robeznieks
  It''s a given that using medical scribes will reduce data-entry time for physicians. But the myriad benefits this produces for patients and physicians are now being quantified by emerging research.
20. Privacy, security guidelines aim to bolster use of mHealth - 10/25/2018
 American Medical Association (AMA) News by Andis Robeznieks
  Privacy and security guidelines aimed at securing the protected health information and personal, identifiable data of mobile health app users have been released for public comment by Xcertia, a nonprofit founded by the AMA and other major health and technology organizations.
<<  <  [1[2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  >  >>
 


Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email : medalls@medalls.com